Incidences of pneumonitis associated with the combination of radiotherapy and immune checkpoint inhibitors in lung cancer: a systematic review and meta-analysis.
Clicks: 75
ID: 281562
2025
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
22.2
/100
75 views
24 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #43 of 45 articles by views in Frontiers in oncology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Recently, the therapeutic effects of the combination of radiotherapy (RT) and immune checkpoint inhibitors (ICIs) on lung cancer (LC) have piqued the interest of the scientific community. Clinical trials have confirmed that RT and ICI therapy exert synergistic therapeutic effects. However, treatment with the RT-ICI combination can lead to the occurrence of pneumonitis, limiting the implementation of the treatment plan, decreasing the tumor control rate, and inducing immunosuppressive pneumonitis and radiation pneumonitis. Therefore, this study performed a systematic review and meta-analysis of pneumonitis prevalence among patients with LC who were treated with a combination of ICIs and chemoradiotherapy (CRT). Literature published between January 1, 2010, and October 15, 2023, were searched in the PubMed, Cochrane Library, Embase, and Web of Science databases by two authors. The primary outcomes analyzed in this study were the incidence rates of all-grade pneumonitis and ≥ grade 3 pneumonitis. This study analyzed 53 studies involving 4226 patients. The pooled incidence rates of all-grade and ≥ grade 3 pneumonitis were 36.0% (95% confidence interval (CI): 30.0-41.0) and 3.0% (95% CI: 2.0-4.0), respectively. The all-grade pneumonitis incidence rates in Asian patients (51%; 95% CI: 38%-63%) were higher than those in non-Asian patients (26%; 95% CI: 22%-31%). Conventional RT was associated with higher rates of all-grade pneumonitis than stereotactic body radiation therapy (SBRT) (37%; 95% CI: 31%-42% vs. 26.0%; 95% CI: 20%-33%). Additionally, sequential immunotherapy was associated with higher rates of all-grade pneumonitis than concurrent immunotherapy ((38%; 95% CI: 31%-45% vs. 25.0%; 95% CI: 20%-30%)). Furthermore, anti-PD1 therapy was associated with higher rates of all-grade pneumonitis than PD-L1 therapy (40%; 95% CI: 32%-47% vs. 20.0%; 95% CI: 16%-24%). Similar incidence rates of ≥ grade 3 pneumonitis were reported in all included studies. This study suggests that the combination of ICIs and RT/CRT is a safe and feasible therapeutic regimen for patients with LC. However, these findings are based on observational studies and are associated with significant heterogeneity. Hence, large prospective studies are needed to validate the findings of this meta-analysis. https://www.crd.york.ac.uk/PROSPERO/#myprospero, identifier CRD42023485613.
| Reference Key |
li2025incidences
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Li, Jing; Zheng, Lingli; Liu, Chaomin; Liu, Wei; Li, Yan; Wang, Dan; Jiang, Ting |
| Journal | Frontiers in oncology |
| Year | 2025 |
| DOI |
10.3389/fonc.2025.1365966
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.